Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) Meeting Abstract
| Authors: | Seymour, J. F.; Davids, M. S.; Pagel, J. M.; Kahl, B. S.; Wierda, W. G.; Miller, T. P.; Gerecitano, J. F.; Kipps, T. J.; Anderson, M. A.; Huang, D. C. S.; Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; Yang, J.; Busman, T. A.; Dunbar, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.; Roberts, A. W. |
| Abstract Title: | Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) |
| Meeting Title: | 55th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 122 |
| Issue: | 21 |
| Meeting Dates: | 2013 Dec 7-10 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2013-11-15 |
| Language: | English |
| ACCESSION: | WOS:000331385002043 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V122.21.872.872 |
| Notes: | Meeting Abstract: 872 -- Source: Wos |
